Taiko Pharmaceutical Co (TSE:4574) Issuance of Debt: 円0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
63 GF Score
Price 円263.00
GF Value 円264.04
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Issuance of Debt?

Taiko Pharmaceutical Co TSE:4574 -0.38% 63 Issuance of Debt is 円0 Mil as of Jun. 2026. GuruFocus rates TSE:4574 with a GF Score™ of 63/100 and a GF Value™ of 円264.04 (Fairly Valued). The stock has 4 warning signs investors should review.

Taiko Pharmaceutical Co's Issuance of Debt for the three months ended in Jun. 2026 was 円0 Mil.

Taiko Pharmaceutical Co's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was 円0 Mil.

Taiko Pharmaceutical Co Issuance of Debt Related Terms

Taiko Pharmaceutical Co Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Issuance of Debt Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,000.00 0.00 500.00 0.00 0.00

Taiko Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4574
63GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of 円0 Mil mean?
Taiko Pharmaceutical Co (TSE:4574) has a Issuance of Debt of 円0 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Issuance of Debt too high?
Taiko Pharmaceutical Co's current Issuance of Debt is 円0 Mil. Overall, Taiko Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Issuance of Debt compare to ZTS?
Taiko Pharmaceutical Co's Issuance of Debt of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Drug Manufacturers company?
A good Issuance of Debt depends on the Drug Manufacturers industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Issuance of Debt is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Fairly Valued. The stock's GF Value™ is 円264.04, compared to a current price of 円263.00 — trading 0.4% below its estimated fair value. The current Issuance of Debt is 円0 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Issuance of Debt is 円0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円263.00 is trading 0.4% below its estimated GF Value™ of 円264.04. GuruFocus considers Taiko Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4574:

  • Issuance of Debt: 円0 Mil
  • GF Value™: 円264.04 vs. price of 円263.00 (0.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
63GF Score

Get the complete analysis for TSE:4574

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円263.00
Price
円264.04
GF Value